BS148 Reduces the Aggressiveness of Metastatic Melanoma via Sigma-2 Receptor Targeting
The management of advanced-stage melanoma is clinically challenging, mainly because of its resistance to the currently available therapies. Therefore, it is important to develop alternative therapeutic strategies. The sigma-2 receptor (S2R) is overexpressed in proliferating tumor cells and represents a promising vulnerability to target. Indeed, we have recently identified a potent S2R modulator (BS148) that is effective in melanoma. To elucidate its mechanism of action, we designed and synthesized a BS148 fluorescent probe that enters SK-MEL-2 melanoma cells as assessed using confocal microscopy analysis. We show that S2R knockdown significantly reduces the anti-proliferative effect induced by BS148 administration, indicating the engagement of S2R in BS148-mediated cytotoxicity. Interestingly, BS148 treatment showed similar molecular effects to S2R RNA interference-mediated knockdown. We demonstrate that BS148 administration activates the endoplasmic reticulum stress response through the upregulation of protein kinase R-like ER kinase (PERK), activating transcription factor 4 (ATF4) genes, and C/EBP homologous protein (CHOP). Furthermore, we show that BS148 treatment downregulates genes related to the cholesterol pathway and activates the MAPK signaling pathway. Finally, we translate our results into patient-derived xenograft (PDX) cells, proving that BS148 treatment reduces melanoma cell viability and migration. These results demonstrate that BS148 is able to inhibit metastatic melanoma cell proliferation and migration through its interaction with the S2R and confirm its role as a promising target to treat cancer.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
International journal of molecular sciences - 24(2023), 11 vom: 02. Juni |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sorbi, Claudia [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
145891-90-3 |
|---|
| Anmerkungen: |
Date Completed 12.06.2023 Date Revised 12.06.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3390/ijms24119684 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM358003881 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM358003881 | ||
| 003 | DE-627 | ||
| 005 | 20231226073820.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/ijms24119684 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1193.xml |
| 035 | |a (DE-627)NLM358003881 | ||
| 035 | |a (NLM)37298633 | ||
| 035 | |a (PII)9684 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sorbi, Claudia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a BS148 Reduces the Aggressiveness of Metastatic Melanoma via Sigma-2 Receptor Targeting |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.06.2023 | ||
| 500 | |a Date Revised 12.06.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The management of advanced-stage melanoma is clinically challenging, mainly because of its resistance to the currently available therapies. Therefore, it is important to develop alternative therapeutic strategies. The sigma-2 receptor (S2R) is overexpressed in proliferating tumor cells and represents a promising vulnerability to target. Indeed, we have recently identified a potent S2R modulator (BS148) that is effective in melanoma. To elucidate its mechanism of action, we designed and synthesized a BS148 fluorescent probe that enters SK-MEL-2 melanoma cells as assessed using confocal microscopy analysis. We show that S2R knockdown significantly reduces the anti-proliferative effect induced by BS148 administration, indicating the engagement of S2R in BS148-mediated cytotoxicity. Interestingly, BS148 treatment showed similar molecular effects to S2R RNA interference-mediated knockdown. We demonstrate that BS148 administration activates the endoplasmic reticulum stress response through the upregulation of protein kinase R-like ER kinase (PERK), activating transcription factor 4 (ATF4) genes, and C/EBP homologous protein (CHOP). Furthermore, we show that BS148 treatment downregulates genes related to the cholesterol pathway and activates the MAPK signaling pathway. Finally, we translate our results into patient-derived xenograft (PDX) cells, proving that BS148 treatment reduces melanoma cell viability and migration. These results demonstrate that BS148 is able to inhibit metastatic melanoma cell proliferation and migration through its interaction with the S2R and confirm its role as a promising target to treat cancer | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a TMEM97 | |
| 650 | 4 | |a cancer | |
| 650 | 4 | |a melanoma | |
| 650 | 4 | |a sigma-2 agonist | |
| 650 | 4 | |a sigma-2 receptor | |
| 650 | 7 | |a sigma-2 receptor |2 NLM | |
| 650 | 7 | |a Receptors, sigma |2 NLM | |
| 650 | 7 | |a Transcription Factor CHOP |2 NLM | |
| 650 | 7 | |a 147336-12-7 |2 NLM | |
| 650 | 7 | |a Activating Transcription Factor 4 |2 NLM | |
| 650 | 7 | |a 145891-90-3 |2 NLM | |
| 650 | 7 | |a eIF-2 Kinase |2 NLM | |
| 650 | 7 | |a EC 2.7.11.1 |2 NLM | |
| 700 | 1 | |a Belluti, Silvia |e verfasserin |4 aut | |
| 700 | 1 | |a Atene, Claudio Giacinto |e verfasserin |4 aut | |
| 700 | 1 | |a Marocchi, Federica |e verfasserin |4 aut | |
| 700 | 1 | |a Linciano, Pasquale |e verfasserin |4 aut | |
| 700 | 1 | |a Roy, Neena |e verfasserin |4 aut | |
| 700 | 1 | |a Paradiso, Elia |e verfasserin |4 aut | |
| 700 | 1 | |a Casarini, Livio |e verfasserin |4 aut | |
| 700 | 1 | |a Ronsisvalle, Simone |e verfasserin |4 aut | |
| 700 | 1 | |a Zanocco-Marani, Tommaso |e verfasserin |4 aut | |
| 700 | 1 | |a Brasili, Livio |e verfasserin |4 aut | |
| 700 | 1 | |a Lanfrancone, Luisa |e verfasserin |4 aut | |
| 700 | 1 | |a Imbriano, Carol |e verfasserin |4 aut | |
| 700 | 1 | |a Di Rocco, Giulia |e verfasserin |4 aut | |
| 700 | 1 | |a Franchini, Silvia |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of molecular sciences |d 2008 |g 24(2023), 11 vom: 02. Juni |w (DE-627)NLM185552161 |x 1422-0067 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2023 |g number:11 |g day:02 |g month:06 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/ijms24119684 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2023 |e 11 |b 02 |c 06 | ||